Integrase inhibitors for the treatment of HIV infection

Current Opinion in Drug Discovery and Development

Volumn 11, Issue 4, 2008, Pages 471-479

  Pace, P ^a   Rowley, M ^a  

^a IRBM   (Italy)

Author keywords

AIDS; HIV; Integrase; MK 0518; N methylpyrimidones; Protein binding; Raltegravir

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; BA 011; BMS 538158; BMS 707035; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; GS 9160; GS 9224; INT 349; INTEGRASE; INTEGRASE INHIBITOR; L 870812; LACTAM DERIVATIVE; LAMIVUDINE; MARAVIROC; MK 2048; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; NELFINAVIR; NEVIRAPINE; PYRIDAZINE DERIVATIVE; RALTEGRAVIR; RITONAVIR; S 247303; S 265744; S 349572; S 364735; UNINDEXED DRUG; V 165; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GENE INSERTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; REVIEW; SINGLE DRUG DOSE; VIRUS CELL INTERACTION;

ANIMALS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MOLECULAR STRUCTURE; PYRROLIDINONES; TREATMENT OUTCOME;

EID: 46749105503     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. 2007 AIDS epidemic update: UNAIDS Secretariat, Geneva, Switzerland. www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/ EpiUpdArchive/2007
2. Pomerantz RJ, Horn DL: Twenty years of therapy for HIV-1 infection. Nature Med (2003) 9(7):867-873.
3. Wood A, Armour D: The discovery of the CCR5 receptor antagonist UK-427857. A new agent for the treatment of HIV infection and AIDS. Prog Med Chem (2005) 43:239-271.
4. Manfredi R, Sabbatani S: A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20). Curr Med Chem (2006) 13(20):2369-2384.
5. Cohen J: Therapies. Confronting the limits of success. Science (2002) 296(5557):2320-2324.
6. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M et al: Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med (2002) 347(6):385-394.
7. Pommier Y, Johnson AA, Marchand C: Integrase inhibitors to treat HIV/Aids. Nat Rev Drug Discov (2005) 4(3):236-248.
8. Wai JS, Egbertson MS, Payne LS, Fisher TE, Embrey MW, Tran LO, Melamed JY, Langford HM, Guare JP Jr, Zhuang L, Grey VE et al: 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J Med Chem (2000) 43(26):4923-4926. • Describes the chemistry and SAR of a series of diketo acids as HIV-1 integrase inhibitors.
9. Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, Vacca JP, Handt L, Motzel SL, Klein HJ, Dornadula G et al: Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science (2004) 305(5683):528-532. •• Describes the efficacy of L-870812 in rhesus macaques that are infected with the simian-human immunodeficiency virus (SHIV) and provides the first evidence of in vivo efficacy for integrase inhibitors in retroviral infections.
10. Hazuda DJ, Anthony NJ, Gomez RP, Jolly SM, Wai JS, Zhuang L, Fisher TE, Embrey M, Guare JP Jr, Egbertson MS, Vacca JP et al: A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci USA (2004) 101(31):11233-11238. •• Describes the identification and characterization of L-870810 and its sensitivity to resistance mutations, thus providing a structural basis and rationale for developing integrase inhibitors with the potential for unique resistance profiles.
11. Rowley M: The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection. Prog Med Chem (2008) 46:1-28.
12. Behrens S-E, Tomei L, De Francesco R: Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J (1996) 15(1):12-22.
13. Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De Francesco R, Rey FA: Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA (1999) 96(23):13034-13039.
14. Lindenbach BD, Rice CM: Unravelling hepatitis C virus replication from genome to function. Nature (2005) 436(7053):933-938.
15. Rice P, Craigie R, Davies DR: Retroviral integrases and their cousins. Curr Opin Struct Biol (1996) 6(1):76-83.
16. Grobler JA, Stillmock K, Hu B, Witmer M, Felock P, Espeseth AS, Wolfe A, Egbertson M, Bourgeois M, Melamed J, Wai JS et al: Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the acive site of phosphotransferase enzymes. Proc Natl Acad Sci USA (2002) 99(10):6661-6666. • Demonstrates that the binding of diketo acids to integrase is mediated by the interaction of the acid functionality with metals in the active site.
17. Summa V, Petrocchi A, Pace P, Matassa VG, De Francesco R, Altamura S, Tomei L, Koch U, Neuner P: Discovery of α,γ-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. J Med Chem (2004) 47(1):14-17.
18. Summa V, Petrocchi A, Matassa VG, Taliani M, Laufer R, De Francesco R, Altamura S, Pace P: HCV NS5b RNA-dependent RNA polymerase inhibitors: From α,γ-diketoacids to 4,5-dihydroxypyrimidine or 3-methyl-5- hydroxypyrimidinonecarboxylic acids. Design and synthesis. J Med Chem (2004) 47(22):5336-5339. •• Describes the design and synthesis of pyrimidines as novel heterocyclic mimetics of the diketo acid moiety.
19. Petrocchi A, Koch U, Matassa VG, Pacini B, Stillmock KA, Summa V: From dihydroxypyrimidine carboxylic acids to carboxamide HIV-1 integrase inhibitors: SAR around the amide moiety. Bioorg Med Chem Lett (2007) 17(2):350-353.
20. Pace P, Di Francesco ME, Gardelli C, Harper S, Muraglia E, Nizi E, Orvieto F, Petrocchi A, Poma M, Rowley M, Scarpelli R et al: Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors. J Med Chem (2007) 50(9):2225-2239.
21. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L et al: Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naïve HIV-1-infected individuals. J Acquir Immune Defic Syndr (2006) 43(5):509-515.
22. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD: Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomized controlled trial. Lancet (2007) 369(9569):1261-1269. • Provides clinical results for raltegravir in treatment-experienced patients.
23. Egbertson MS: HIV integrase inhibitors: From diketoacids to heterocyclic templates: A history of HIV integrase medicinal chemistry at Merck West Point and Merck Rome (IRBM). Curr Top Med Chem (2007) 7(13):1251-1272. • Describes the development of diketo acids into a variety of heterocyclic templates for integrase inhibitors.
24. Wai J, Fisher T, Embrey M, Egbertson M, Vacca J, Hazuda D, Miller M, Witmer M, Gabryelski L, Lyle T: Next generation of inhibitors of HIV-1 integrase strand transfer inhibitor: Structural diversity and resistance profiles. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, USA (2007):87.
25. Billich A: S-1360 Shionogi-GlaxoSmithKline. Curr Opin Investig Drugs (2003) 4(2):206-209. • Provides a summary of many aspects of S-1360.
26. Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, Sugimoto H, Endo T, Murai H, Davies DR: Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc Natl Acad Sci USA (1999) 96(23):13040-13043.
27. Rosemond MJ, St John-Williams L, Yamaguchi T, Fujishita T, Walsh JS: Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: Role of human liver cytosolic aldo-keto reductases. Chem Biol Interact (2004) 147(2):129-139.
28. Sunila Reddy Y, Min SS, Borland J, Song I, Lin J, Palleja S, Symonds WT: Safety and pharmacokinetics of GSK364735, a human immunodeficiency virus type 1 integrase inhibitor, following single and repeated administration in healthy adult subjects. Antimicrob Agents Chemother (2007) 51(12):4284-4289.
29. Teshirogi I: Heading toward the real growth. Merril Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 2008, New York, NY, USA (2008). www.shionogi.co.jp/ir_en/explanatory/pdf/e_080206. pdf
30. Sato M, Motomura T, Aramaki H, Matsuda T, Yamashita M, Ito Y, Kawakami H, Matsuzaki Y, Watanabe W, Yamataka K, Ikeda S et al: Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem (2006) 49(5):1506-1508. • Describes the SAR for elvitegravir.
31. Lataillade M, Chiarella J, Kozal MJ: Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antiviral Ther (2006) 12(4):563-570.
32. DeJesus E, Berger D, Markowitz M, Cohen C, Hawkins T, Ruane P, Elion R, Farthing C, Zhong L, Cheng AK, McColl D et al: Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naïve and treatment-experienced patients. J Acquir Immune Defic Syndr (2006) 43(1):1-5.
33. Ramanathan S, Shen G, Hinkle J, Enejosa J, Kearney BP: Pharmacokinetics of coadministerd ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir. J Acquir Immune Defic Syndr (2007) 46(2):160-166. • Describes the results of relevant clinical studies of elvitegravir.
34. Zolopa AR, Mullen M, Berger D, Ruane P, Hawkins T, Zhong L, Chuck S, Enejosa J, Kearney B, Chang A: The HIV integrase inhibitor GS-9137 demonstrates potent antiretroviral activity in treatment-experienced patients. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, USA (2007):143LB.
35. Daelemans D, Lu R, De Clercq E, Engelman A: Characterization of a replication-competent, integrase-defective human immunodeficiency virus (HIV)/simian virus 40 chimera as a powerful tool for the discovery and validation of HIV integrase inibitors. J Virol (2007) 81(8):4381-4385.
36. Gilead Sciences Q4 2006 Earnings Call Transcript: Seeking Alpha (2007). seekingalpha.com/article/25725-gilead-sciences-q4-2006-earnings-call- transcript?page=1
37. Leh H, Thomas CM, Zouhiri F, Chéret A, Mousçadet JF: Styrylquinolines derivatives targeting HIV integrase are in vitro synergic with reverse transcriptase inhibitors and diketo acids. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2005):547.
38. Deprez E, Barbe S, Kolaski M, Leh H, Zouhiri F, Auclair C, Brochon JC, Le Bret M, Mouscadet JF: Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro. Mol Pharmacol (2004) 65(1):85-98.
39. Bonnenfant S, Thomas CM, Vita C, Subra F, Deprez E, Zouhiri F, Desmaële D, D'Angelo J, Mouscadet JF, Leh H: Styrylquinolines, integrase inhibitors acting prior to integration: A new mechanism of action for anti-integrase agents. J Virol (2004) 78(11):5728-5736.
40. Pannecouque C, Pluymers W, Van Maele B, Tetz V, Cherepanov P, De Clercq E, Witvrouw M, Debyser Z: New class of HIV integrase inhibitors that block viral replication in cell culture. Curr Biol (2002) 12(14):1169-1177.
41. NCT00397566: A multiple, ascending dose study of BMS-707035 in HIV-1 infected subjects. ClinicalTrials.gov, US National Institutes of Health, Bethseda, MA, USA (2008). www.clinicaltrials.gov/ct2/show/NCT00397566?term= NCT00397566&rank=1
42. Wu JJ, Milot G, Gouveia K, Dandanche S, Xiao Y, Ge M, Oudanonh T, Bouchard JE, Stranix BR: Pyrazolopyridine compounds as novel HIV-1 integrase inhibitors. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2007):H-1045.
43. Williams KL, Zhang Y, Shkriabai N, Karki RG, Nicklaus MC, Kotrikadze N, Hess S, Le Grice SF, Craigie R, Pathak VK, Kvaratskhelia M: Mass spectrometric analysis of the HIV-1 integrase-pyridoxal 5′-phosphate complex reveals a new binding site for a nucleotide inhibitor. J Biol Chem (2005) 280(9):7949-7955.
44. Wu JJ, Milot G, Dandache S, Gouveia K, Xiao Y, Yelle J, Sevigny G, Dubois A, Tian B, Perron V, Herbart D et al: Novel small molecule inhibitors of HIV-1 integrase. 16th International HIV Drug Resistance Workshop, Barbados, West Indies (2007):S8.
45. Avexa Ltd: Half Year Results 31 December 2007. Press Release (2008) February 21.
46. Patil S, Kamath S, Sanchez T, Neamati N, Schinazi RF, Buolamwini JK: Synthesis and biological evaluation of novel 5(H)- phenantridin-6-ones, 5(H)-phenantridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors. Bioorg Med Chem (2007) 15(3):1212-1228.
47. Uchil V, Seo B, Nair V: A novel strategy to assemble the β-diketo acid pharmacophore of HIV integrase inhibitors on purine nucleobase scaffold. J Org Chem (2007) 72(22):8577-8579.
48. Chi G, Nair V, Semenova E, Pommier Y: A novel diketo phosphonic acid that exhibits specific, strand-transfer inhibition of HIV integrase and anti-HIV activity. Bioorg Med Chem Lett (2007) 17(5):1266-1269.
49. Walker MA, Johnson T, Naidu BN, Banville J, Remillard R, Plamondon S, Martel A, Li C, Torri A, Samanta H, Lin Z et al: Benzyl amideketoacid inhibitors of HIV-integrase. Bioorg Med Chem Lett (2007) 17(17):4886-4890.
50. Fisher TE, Kim B, Staas DD, Lyle TA, Young SD, Vacca JP, Zrada MM, Hazuda DJ, Felock PJ, Schleif WA, Gabryelski LJ et al: 8-Hydroxy-3,4- dihydropyrrolo[1,2-a]pyrazine-1(2H)-one HIV-1 integrase inhibitors. Bioorg Med Chem Lett (2007) 17(23):6511-6515.
51. Wai JS, Kim B, Fisher TE, Zhuang L, Embrey MW, Williams PD, Staas DD, Culberson C, Lyle TA, Vacca JP, Hazuda DJ et al: Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors. Bioorg Med Chem Lett (2007) 17(20):5595-5599.
52. Bansal R, Karthikeyan C, Moorthy N, Trivedi P: QSAR analysis of some phthalimide analogues based inhibitors of HIV-1 integrase. ARKIVOC (2007) 15(14):66-81.
53. Ferro S, Barreca ML, De Luca L, Rao A, Monforte AM, Debyser Z, Witvrouw M, Chimirri A: New 4-[(1-benzyl-1H-indol-3-yl) carbonyl]-3-hydroxyfuran-2(5H)-ones, β-diketo acid analogs as HIV-1 integrase inhibitors. Ark Pharm (2007) 340(6):292- 298.
54. Kawasuji T, Fuji M, Yoshinaga T, Sato A, Fujiwara T, Kiyama R: 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as advanced inhibitors of HIV integrase. Bioorg Med Chem (2007) 15(16):5487-5492.
55. Dayam R, Al-Mawsawi LQ, Neamati N: Substituted 2-pyrrolinone inhibitors of HIV-1 integrase. Bioorg Med Chem Lett (2007) 17(22):6155-6159.
56. MERCK & CO INC (Wai JS, Vacca JP, Zhuang L, Kim B, Lyle TA, Wiscount CM, Egbertson MS, Neilson LA, Embrey M, Fisher TE, Staas DD): HIV integrase inhibitors. WO-2005110415 (2005).
57. SMITHKLINE BEECHAM CORPORATION/S HIONOGI & CO LTD (Johns BA, Boros EE, Kawasuji T, Koble CS, Kurose N, Murai H, Sherril RG, Weatherhead JG): HIV integrase inhibitors. WO-2005077050 (2005).
58. BRISTOL-MYERS SQUIBB COMPANY (Nugent WA, Zhu K, Simpson JH, Delaney EJ): Process for the preparation of Z-5-carboxymethylene-1,3-dioxolan-4-ones. US-20060047129 (2006).
59. BRISTOL-MYERS SQUIBB COMPANY (Naidu NB, Ueda Y, Connolly TP): Preparation of pyrimidine derivatives as HIV integrase inhibitors. WO-2007064619 (2007).
60. BRISTOL-MYERS SQUIBB COMPANY (Nalker MA, Li C, Grant-Young KA, Matiskelle JD, Naidu NB, Banville J, Beaulieu F, Ovellet C, Pendri A, Remillard R, Ueda Y et al): Preparation of fused oxopyrimidinecarboxamides as HIV integrase inhibitors. WO-2008002959 (2008).
61. AMBRILIA BIOPHARMA INC (Stranix BR, Herbart D, Perron V): Pyrazolo[3,4-b]pyridin-2-yl]benzoic acid derivatives as HIV integrase inhibitors. WO-2007000043 (2007).
62. AVEXA LTD (Choi N, Deadman JJ, Issa W, Jones ED, Macfarlane K, Rhodes DI): Integrase inhibitors - 1. WO-2007124544 (2007).
63. AVEXA LTD/MONASH UNIVERSITY (Crosby I, Choi N, Deadman JJ, Issa W, Jones ED, Macfarlane K, Rhodes DI): Integrase inhibitors - 2. WO-2007124545 (2007).
64. AVEXA LTD (Rhodes DI, Macfarlane K, Jones ED, Issa W, Deadman JJ, Choi N): Integrase inhibitors - 3. WO-2007124546 (2007).
65. PFIZER PRODUCTS INC (Dress KR, Johnson TW, Plewe MB, Tanis SP, Tran KT): Inhibitors of the HIV integrase enzyme. WO-2007039802 (2007).
66. PFIZER PRODUCTS INC (Dress KR, Johnson TW, Plewe MB, Tanis SP, Zhu H): Inhibitors of the HIV integrase enzyme. WO-2007042883 (2007).